Cover Image
市場調查報告書

市場進入的課題:HIV (歐盟5國)

Market Access Impact: HIV (EU5) 2017

出版商 FirstWord 商品編碼 497069
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
市場進入的課題:HIV (歐盟5國) Market Access Impact: HIV (EU5) 2017
出版日期: 2017年04月01日 內容資訊: 英文
簡介

本報告提供歐盟5國 (法國、義大利、德國、西班牙、英國)的150名感染疾病專門醫生的HIV治療藥的處方趨勢調查,市場進入的各種障礙與對處方的影響,主要9品牌藥的處方相關比較分析、個別分析。

調查課題

  • 各種障礙的市場進入的影響
    • 醫生最大量開立處方的品牌為何?
    • 市場障礙怎麼影響著處方的決策?
    • 各種障礙有影響力的差異嗎?
  • 各品牌的障礙的影響
    • 開立各品牌處方的醫生數是多少?未開立處方但考慮的數量是多少?
    • 不開立處方的理由為何?其替代處方為何?
    • 互相爭奪市場佔有率的競爭品牌為何?

調查對象

  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Isentress (raltegravir; Merck Sharp & Dohme)
  • Prezista (darunavir; Janssen Cilag)
  • Reyataz (atazanavir; BMS)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Viread (tenofovir disoproxil fumarate; Gilead)
目錄

HIV drug market barriers: A help or a hindrance?

Today's tightly packed European HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market entrants continue to arrive - the most recent from Gilead - hoping to disrupt the status quo. But how are market barriers impacting prescribing choices, and what effect does that have on market share? Are newer players changing market dynamics?

Use this latest report to understand the barriers driving market share shifts. Market Access Impact: HIV (EU5) features 9 big-hitter named HIV drugs from Gilead, Janssen Cilag, Merck Sharp & Dohme, BMS and ViiV Healthcare.

Top Takeaways

  • One step ahead: Some brands gain advantage when competitors have not made it on to the formulary. But which single brand benefits the most?
  • Visibility isn't the problem: The proportion of physicians claiming not to know about these 9 HIV brands is negligible. With such high awareness, what else is impacting prescribing behaviour?
  • It's not plain sailing for some: Some drugs have very few prescribing barriers, however 1 in 10 physicians say this drug has 3 or more barriers. Which drug?
  • The devil is in the detail: 17% of EU prescribing decisions are affected by market barriers, but no single barrier stands out from the rest. Find out how to fine tune strategy in a tight-knit market.
  • New kids on the block: How does prescribing of recent market entrants compare to more established drugs? Which market barriers are already associated with Descovy and Genvoya?

Insight into 9 Major HIV Drugs

  • Descovy (emtricitabine/tenofovir alafenamide; Gilead)
  • Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
  • Isentress (raltegravir; Merck Sharp & Dohme)
  • Prezista (darunavir; Janssen Cilag)
  • Reyataz (atazanavir; BMS)
  • Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
  • Viread (tenofovir disoproxil fumarate; Gilead)

Lifting the lid on Market Access issues

Market Access Impact: HIV gives a unique insight into the issues affecting the major HIV drug manufacturers. You'll learn:

How barriers affect market access:

  • Which HIV brands are physicians prescribing the most?
  • How are prescribing decisions being affected by market barriers?
  • Are some barriers having more impact than others?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they choose instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 infectious disease specialists and general practitioners in the EU5 (France, Italy, Germany, Spain, UK) .

All respondents have:

  • Been practising for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 HIV patients in total in the last month

We conducted the survey between 2nd and 7th March 2017.

Back to Top